OR WAIT null SECS
May 16, 2023
The data, published in the scientific journal Nature, demonstrated that half of patients developed T cells that could potentially fight pancreatic ductal adenocarcinoma.
May 04, 2023
Vibha Jawa, executive director at Bristol Myers Squibb, discusses foreign epitopes recognition from what should be fully human antibody therapies.
April 15, 2023
The recent success of mRNA vaccines has opened the door for further and future development of nucleic acid-based therapies.
Actions combatting the next pandemic must be diverse, reliable, and sustainable.
Unique solutions are required to protect inherently unstable messenger RNA.
This article reviews a range of techniques available for separative analysis of mRNA therapeutics, their associated impurities, and delivery vehicles.
Considerable efforts have been made over the years to resolve the key issues of stability and delivery of RNA-based therapeutics.
The complexity of the RNA production process creates challenges.
April 06, 2023
Nicole Lewis, PVP Program Manager at Boston Children's Hospital, discusses the science behind precision vaccines, a form of personalized vaccines.
March 02, 2023
Advances in vaccine development are creating partnerships and stimulating clinical trials to develop new mRNA applications.